Latest Financial Position News

EZZ Life Science Holdings Limited reported a slight increase in revenue for the year ended June 2025, while net profit experienced a modest decline. The company also boosted its net tangible assets per share and maintained steady dividend payments.

Seafarms Group Limited reported a reduced loss of $11.7 million for FY2025, despite a 43% drop in revenue and ongoing legal challenges surrounding Project Sea Dragon. Production setbacks from flooding and subdued market demand weighed heavily on results.

Cardiex Limited’s FY2025 results reveal a sharp 67% revenue decline driven by the prior year’s one-off clinical trial payment, while net losses nearly doubled despite ongoing cost reduction efforts and significant capital raises.

Senetas Corporation has reported a transformative FY2025 with a $27.8 million net profit driven by the divestment of its Votiro business, while its core network encryption operations remain profitable and cash generative.

ZMM has reported a significant turnaround with a $815,877 net profit for FY2025, reversing last year’s $3.25 million loss, though net tangible assets per security have halved and auditors flag going concern uncertainty.

Nexion Group Ltd has reported a significantly reduced net loss for FY25, driven by major asset sales and a strategic pivot towards AI and business intelligence. The company’s divestments are expected to strengthen its balance sheet and provide steady cash inflows.

TZ Limited reported a challenging FY25 with a $3.52 million net loss, impacted by integration costs and US tariff disruptions. Despite setbacks, the company completed the Keyvision acquisition and anticipates a strong revenue rebound in FY26.

Energy World Corporation Ltd reports a remarkable turnaround to a $346 million profit for FY25, driven by a $390 million gain from debt restructuring and the sale of a key Indonesian asset. The company faces funding challenges as it advances LNG and power projects in Southeast Asia.

DTI Group Ltd reported an 11% revenue increase and secured a $4 million Adelaide Metro contract, alongside a $2.69 million capital raise to fuel growth. The company also deepened global partnerships and enhanced its technology platform during FY25.

Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.

Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.